Cytoreductive nephrectomy preceding adjuvant immunotherapy for metastatic renal cell carcinoma: 8 years' experience in a UK tertiary referral centre

Patients are at significant risk of failure to proceed to adjuvant immunotherapy following CN for mRCC, most commonly due to poor performance status postoperatively. Laparoscopic CN is shown to be safe and effective in well-selected patients. As new targeted treatments for mRCC emerge and their use in combination with CN is evaluated, a detailed and multidisciplinary approach to selection of these patients will continue to be crucial.